Combining anti-gene γPNA with small molecules and RNA inhibitors: A strategy to enhance anti-tumor efficacy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeting oncogenes like c-Myc via genomic DNA is a key cancer therapy strategy.
• Gamma peptide nucleic acids (γPNAs) targeting c-Myc DNA show preclinical efficacy.
• Enhancing anti-tumor effects of γPNAs requires combination therapies.

Purpose of the Study:

• To investigate combination treatments integrating γPNAs with c-Myc inhibitors.
• To evaluate synergistic anti-tumor effects of combined therapies.
• To explore novel therapeutic strategies for c-Myc-driven cancers.

Main Methods:

• Combination of γPNAs with histone deacetylase inhibitors (HDACis).
• Integration of γPNAs with MYC/MAX inhibitors.
• Co-delivery of γPNAs with small interfering RNA (siRNA).
• Assessment of small molecules targeting c-Myc indirectly.

Main Results:

• Synergistic reduction in c-Myc mRNA, protein, and cell viability with HDACis.
• Enhanced anti-tumor efficacy with MYC/MAX inhibitors, lowering IC50.
• Significant downregulation of c-Myc expression via γPNA-siRNA co-delivery.
• High synergy scores observed with indirect c-Myc targeting small molecules.

Conclusions:

• Combination of anti-gene γPNAs with small molecules or antisense approaches is a potent strategy.
• This synergistic approach shows significant promise for targeting c-Myc-driven cancers.
• The findings present a promising therapeutic avenue for cancer treatment.